National and international guidelines recommend long-term use of evidence-based medication for management of CHD, such as use of acetylsalicylic acid (ASA), beta blockers, angiotensin-converting enzyme inhibitors (ACEI) and statins, as first-line therapy; or other antiplatelet medication, angiotensin receptor blocker (ARB) or fibrate when first-line therapy is contraindicated.3 The gene discussed is ACE; the disease is coronary artery disorder.